Abstract
Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-line drug. Evidence is building up in favor of fibrates, which are available for off-label use.
Keywords:
Fibrates; Obeticholic acid; Primary biliary colangitis; Treatment.
MeSH terms
-
Chenodeoxycholic Acid / adverse effects
-
Chenodeoxycholic Acid / analogs & derivatives*
-
Chenodeoxycholic Acid / therapeutic use
-
Cholagogues and Choleretics / adverse effects
-
Cholagogues and Choleretics / therapeutic use*
-
Cholangitis / diagnosis
-
Cholangitis / drug therapy*
-
Cholangitis / mortality
-
Drug Therapy, Combination
-
Fibric Acids / adverse effects
-
Fibric Acids / therapeutic use*
-
Humans
-
Liver Cirrhosis, Biliary / diagnosis
-
Liver Cirrhosis, Biliary / drug therapy*
-
Liver Cirrhosis, Biliary / mortality
-
Off-Label Use
-
Treatment Outcome
-
Ursodeoxycholic Acid / adverse effects
-
Ursodeoxycholic Acid / therapeutic use*
Substances
-
Cholagogues and Choleretics
-
Fibric Acids
-
obeticholic acid
-
Chenodeoxycholic Acid
-
Ursodeoxycholic Acid